Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B (LGND) Earnings, Actual EPS, EPS Estimates & Results
This article provides an overview of Ligand Pharmaceuticals, Inc. (LGND) earnings, including estimated and historical EPS and revenue data. The company's upcoming Q3 '26 earnings report is scheduled for November 5th, with an estimated EPS of $2.31 and estimated revenue of $77.95 million. Recent quarters show a mix of beating and missing EPS estimates.
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big
Ligand Pharmaceuticals (NASDAQ: LGND) director Martine Zimmermann has filed a Rule 144 notice to sell 1,200 common shares with an aggregate market value of $342,000. The shares, originating from restricted stock grants in 2024 and 2025, are expected to be sold through Morgan Stanley Smith Barney LLC on or about September 10, 2026. This sale represents a small fraction of the 19,935,609 outstanding shares.
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs
This article provides a detailed shareholding pattern for Ligand Pharmaceuticals Incorporated (LGND), including institutional holdings over several quarters and recent insider trading activities. It shows that institutional investors like Vanguard Group Inc., Macquarie Group Ltd, and BlackRock Inc. hold significant stakes, with varying changes in their holdings over time. The insider trading section lists recent "Sell" transactions by company individuals.
Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock
An officer at Ligand Pharmaceuticals (LGND.US) recently sold a significant amount of common stock, totaling US$9.24 million. This transaction indicates a notable insider trading activity for the company.
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run
Ligand Pharmaceuticals (LGND) stock has seen a significant 337.4% return over the past five years, yet its valuation presents a mixed picture. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 32.4% with an intrinsic value of $427 per share, while its P/E ratio of 29.2x indicates it is overvalued compared to the industry average. This discrepancy highlights differing views on the company's future cash flow stability and growth prospects, especially after the expansion of its royalty portfolio.
Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals
Invesco Ltd. has reported a 6.1% beneficial ownership stake in Ligand Pharmaceuticals Inc., according to a recent SCHEDULE 13G SEC filing. This represents 1,218,846 shares of Ligand's common stock, with Invesco exercising sole voting power over 1,199,033 shares and sole dispositive power over all 1,218,846 shares. The shares are held by Invesco's advisory clients, none of whom hold more than 5% economic ownership individually.
Ligand Pharmaceuticals Q2 Earnings Call Highlights
Ligand Pharmaceuticals reported strong Q2 2026 results, driven by increased royalty revenue and adjusted earnings, and highlighted the strategic acquisition of XOMA Royalty. The company raised its full-year adjusted EPS guidance and outlined significant deployable capital for future business development. Ligand also detailed its expanded commercial portfolio and pipeline catalysts, including several key programs and upcoming trial readouts.
Janus Henderson Group PLC Raises Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND
Janus Henderson Group PLC increased its stake in Ligand Pharmaceuticals Incorporated by 1.5% in the first quarter, now owning over 1 million shares valued at approximately $201.6 million. Institutional investors hold a significant portion of the company's stock, and Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $319. Despite insider selling and a recent earnings miss, Ligand's shares are trading near their 12-month high.
LGND|Ligand Pharmaceuticals Inc|Price:289.855|Chg%:+2.315
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that focuses on enabling scientific advancement through financing and licensing its proprietary technologies, such as Captisol and NITRICIL, to support the clinical development of medicines. The company has a market capitalization of $6.26 billion and a P/E TTM of 40.72. Its Contract Revenue-Other business was the largest revenue source in Q1 2026, generating $66.87 million.
July 2026's Stocks That May Be Priced Below Estimated Value
This article identifies US stocks that may be undervalued based on cash flow analysis, despite a recent market decline. It highlights three specific companies—Ligand Pharmaceuticals (LGND), Legence (LGN), and Belden (BDC)—providing an overview of their operations, estimated discounts to fair value, and growth prospects. The analysis suggests these companies could offer opportunities for investors looking to capitalize on market inefficiencies.
Bessemer Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated $LGND
Bessemer Group Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 358.8% in Q1, now owning 107,859 shares worth $21.5 million. Despite missing recent earnings and revenue estimates, Wall Street maintains a "Moderate Buy" consensus rating with an average price target of $304.00, with several analysts raising their price targets, including Bank of America to $388.00.
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ligand Pharmaceuticals Incorporated (LGDN). It provides a detailed table including each ETF's market value, weight of LGDN in the fund, issuer, management style, focus (e.g., small cap, health care), expense ratio, assets under management (AUM), current price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify funds with exposure to Ligand Pharmaceuticals and assess their characteristics.
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP
Monteverde & Associates PC, an M&A class action firm, is investigating several mergers impacting shareholders of Taylor Morrison Home Corp. (TMHC), Caesars Entertainment, Inc. (CZR), XOMA Royalty Corporation (XOMA), and LiveRamp Holdings, Inc. (RAMP). The firm is encouraging shareholders of these companies to seek information regarding the proposed sale terms and their rights. They emphasize their track record of recovering funds for shareholders through litigation.
Ligand Raises $700M Via 0% Convertible Notes, Adds Note Hedges and $524.34 Strike Warrants
Ligand Pharmaceuticals has successfully completed a $700 million private offering of 0.00% Convertible Senior Notes due 2031 to enhance its liquidity and financial flexibility. To mitigate dilution, the company entered into convertible note hedge transactions covering approximately 2.09 million shares and sold warrants with a $524.34 strike price, covering about 4.19 million shares, to help offset hedging costs. The notes are initially convertible at $334.27 per share and are senior unsecured.
Ligand (NASDAQ: LGND) sets $550M convert deal and $75M buyback
Ligand Pharmaceuticals announced a private offering of $550 million in convertible senior notes due 2031, with an option for an additional $82.5 million. The company plans to use part of the proceeds for convertible note hedge and warrant transactions, repurchase up to $75 million of its common stock, and fund general corporate purposes, including the acquisition of Xoma Royalty Corporation. Concurrently, a Fourth Amendment to its Credit Agreement was made, adjusting minimum Consolidated EBITDA requirements to facilitate this offering.
Is It Too Late To Reassess Ligand Pharmaceuticals (LGND) After A 115% One-Year Rally?
Ligand Pharmaceuticals (LGND) has seen a 115% rally over the last year, prompting a reassessment of its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 34.3% with an intrinsic value of $377.63, while a P/E ratio comparison indicates it might be overvalued at 32.40x against its "Fair Ratio" of 20.62x. The article highlights that different valuation narratives can lead to varying conclusions on its true worth.
JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo
JALAA Equities LP reported the sale of 500 common shares of Ligand Pharmaceuticals (LGND) on June 10, 2026, for $124,980.42. The SEC filing also indicated 4,500 common shares associated with Wells Fargo Clearing Services, originally purchased on April 28, 2005. This Rule 144 notice details the disposition and linked shares, clarifying that the 500 shares sold by JALAA Equities LP were distinct from the Wells Fargo-linked shares.
Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its stockholders approved all proposals at the 2026 annual meeting. These approvals included the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, a non-binding advisory resolution on executive compensation, and an amendment and restatement of the Company’s 2002 Stock Incentive Plan. The approvals demonstrate strong investor support for the company's governance and compensation strategies.
Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants
Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards comprising 836 restricted stock units (RSUs) and 2,938 non-qualified stock options with a strike price of $237.00 per share. These awards, granted on June 5, 2026, fully vest on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date. Following these compensation-related grants, Sabba directly holds 33,629 shares of Ligand common stock, in addition to the newly awarded options.
LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition
Martine Zimmermann, a director at LIGAND PHARMACEUTICALS INC (LGND), reported receiving 836 restricted stock units (RSUs) and non-qualified stock options for 2,938 shares on June 5, 2026, as part of her routine equity compensation. The RSUs and options will fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant date. Additionally, 182 shares were withheld to cover tax liabilities associated with the RSU settlement, a non-market disposition.
Ligand (NASDAQ: LGND) director Jason Haas receives RSU and option grants
Ligand Pharmaceuticals director Jason Haas received 836 restricted stock units (RSUs) and a non-qualified stock option for 2,938 shares as part of his board compensation on June 5, 2026. The RSUs and options fully vest on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date. Following these grants, Haas directly holds 7,442 shares of common stock, and the stock option has an exercise price of $237 per share and expires on June 5, 2036.
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares of Common Stock for approximately $1.14 million on June 1, 2026, by exercising stock options. This transaction represents a liquidity event tied to vesting long-term incentive awards, not an exit from a poor investment, as Reardon maintains significant direct and option holdings. The article highlights Ligand's strong one-year return and growing royalty revenue, advising investors to consider "The Motley Fool Stock Advisor" for top stock picks, though Ligand was not among them.
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares for approximately $1.14 million on June 1, 2026, following the exercise of stock options. This sale, representing 10.78% of his direct holdings, capitalized on Ligand's strong 123.61% one-year total return. Post-transaction, Reardon still holds 41,382 direct shares and 39,444 employee stock options, indicating his interests remain aligned with investors.
Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
Levi & Korsinsky, LLP has launched an investigation into Robinhood, Interactive Brokers, and other trading platforms following trading bans and forced liquidations affecting investors in Ligand Pharmaceuticals (NASDAQ: LGND). These actions, which occurred on January 28, 2021, and also impacted other heavily shorted stocks, caused significant outrage among retail investors and led to calls for Congressional hearings. The law firm is seeking to represent investors who suffered losses due to these limitations imposed by brokerage firms.
LGND - Ligand Pharmaceuticals Inc Stock Price and Quote
This page provides comprehensive financial data and news for Ligand Pharmaceuticals Inc. (LGND), including its stock price, key financial metrics, analyst ratings, and recent corporate announcements. It also details insider trading activities, offering a snapshot of the company's performance and significant events.
Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis
Ligand Pharmaceuticals (Nasdaq:LGND) is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. The company recently agreed to acquire XOMA Royalty Corporation for $739 million, significantly expanding its royalty portfolio and leading to an uplift in its 2026 revenue and EPS outlook. Despite being considered undervalued by analysts, current valuation may already reflect much of the anticipated growth, with key risks including regulatory uncertainty and potential exclusivity loss on some royalty streams.
LGND: XOMA Buy Adds 100+ Assets
Ligand Pharmaceuticals (NASDAQ: LGND) announced the acquisition of XOMA Royalty Corporation (NASDAQ: XOMA) for $739 million, adding over 100 assets to its portfolio. The all-cash transaction, expected to close in Q3 2026, is projected to be immediately accretive to Ligand's earnings, increasing 2026 revenue estimates by $25 million and EPS by $0.50. The acquisition also brings tax benefits and complements recent FDA approvals for Filspari and Tzield, reinforcing Ligand's strategy of building a diversified royalty portfolio.
Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company
Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings, facilitating a Nevada holding company reorganization. This change will result in Ligand's Merger Sub merging with HoldCo, which will then become a wholly owned subsidiary of Ligand. The amendment aims to streamline the acquisition of XOMA Royalty.
Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company
Ligand Pharmaceuticals (LGND) has amended its merger agreement with XOMA Royalty Corporation to include XOMA Royalty Holdings Corporation as a party, formalizing a Nevada holding company reorganization. This amendment clarifies the legal structure of the previously announced acquisition, with XOMA Royalty Holdings surviving as a wholly-owned subsidiary of Ligand. The transaction remains subject to regulatory approvals and XOMA Royalty stockholder approval.
Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND
Stephens Investment Management Group LLC decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 9.6% in the fourth quarter, though it remains its 16th largest holding. Despite positive analyst sentiment and a "Moderate Buy" consensus rating, the company reported mixed quarterly results with EPS and revenue missing estimates. Insider selling by Stephen L. Sabba and Andrew Reardon also occurred within the last 90 days.
Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed
Ligand Pharmaceuticals reported strong Q1 2026 results with royalty revenue increasing 56% year-over-year to $43.0 million, primarily driven by products like Filspari, Ohtuvayre, and Capvaxive. Despite a GAAP net loss of $13.3 million due to non-cash items, adjusted net income rose 30% to $34.6 million. The company reaffirmed its full-year 2026 financial guidance, anticipating $225–$250 million in royalty revenue, and highlighted progress on the pending acquisition of XOMA Royalty.
UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND
UBS Group AG significantly increased its stake in Ligand Pharmaceuticals, purchasing 31,081 additional shares in the fourth quarter, bringing its total holding to 143,067 shares valued at approximately $27.05 million. This comes amidst mixed analyst sentiment, with several firms raising price targets and maintaining buy ratings despite the company missing Q1 EPS and revenue estimates, though revenue still grew year-over-year. Insider selling has also been noted, with the CFO and a director reducing their holdings.
A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination
Ligand Pharmaceuticals (LGND) recently reported an earnings miss, higher royalty revenues, a planned acquisition of XOMA, and a disputed termination of the Viking TR-Beta licensing program. Despite these developments, the stock has shown positive momentum over the past few months and is currently considered undervalued by analysts, trading at $220.48 against a narrative fair value of $246.70. The company's valuation is heavily influenced by its expanding high-margin royalty portfolio, although its P/E ratio of 28.8x is higher than the industry average, suggesting less room for error if expectations are not met.
XOMA Royalty to Be Acquired by Ligand in $39-Per-Share Cash Deal Plus CVRs
XOMA Royalty has agreed to be acquired by Ligand Pharmaceuticals for $39.00 per share in cash, plus contingent value rights (CVRs) from RemainCo LLC. The deal awaits HSR clearance and stockholder approval, with key XOMA stakeholders, including BVF Partners, already committed to supporting the merger, covering about 47% of outstanding shares. A $40 million termination fee for XOMA is part of the merger agreement under specific conditions.
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Orchestra BioMed has received a $15 million investment from Ligand Pharmaceuticals, fulfilling a scheduled tranche of their royalty-based financing agreement and bringing the total capital from Ligand to $40 million. This funding, along with an additional $20 million from Medtronic, will support the continued execution of Orchestra BioMed's pivotal trials for its AVIM Therapy and Virtue Sirolimus AngioInfusion Balloon. Both companies expressed confidence in the progress and potential of these cardiovascular therapies.
Ligand to Participate in May Investor Conferences
Ligand Pharmaceuticals announced its senior management team will participate in several investor conferences throughout May 2026, including the H.C. Wainwright Royalty Company Conference, Bank of America Healthcare Conference, CJS Securities Spring 1x1 Conference, H.C. Wainwright BioConnect Investor Conference, RBC Capital Markets Global Healthcare Conference, Craig-Hallum Institutional Investor Conference, and Benchmark Healthcare House Call Conference. During these events, management will engage in fireside chats and host one-on-one meetings with investors and attendees. Ligand, a leading royalty aggregator, funds biopharmaceutical development programs in exchange for economic interests, boasting a diverse portfolio of over 100 assets.
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the sales of XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. The firm is examining potential violations of federal securities laws and breaches of fiduciary duties to shareholders, particularly regarding whether insiders unfairly benefit from these deals. Shareholders are encouraged to contact the firm to discuss their rights and options.
Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)
Vanguard Portfolio Management has reported a 5.56% beneficial ownership stake in Ligand Pharmaceuticals Inc. (NASDAQ: LGND), holding 1,109,154 shares. The Schedule 13G filing indicates sole voting power over 8,887 shares and sole dispositive power over all 1,109,154 shares. This disclosure, signed by Ashley Grim on May 1, 2026, highlights Vanguard's significant but passive investment in the biotechnology company.
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake
Vanguard Capital Management has filed a Schedule 13G on Ligand Pharmaceuticals Inc. (LGND), reporting a beneficial ownership of 997,637 shares, which represents a 5% stake in the company's common stock as of March 31, 2026. The filing indicates Vanguard possesses sole dispositive power over all these shares and sole voting power over 149,548 shares. This disclosure provides transparency regarding Vanguard's significant investment in Ligand.
[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event
Ligand Pharmaceuticals Inc. (LGND) filed an 8-K report announcing the termination of the TR-Beta Program under its Master License Agreement with Viking Therapeutics, Inc., effective May 4, 2026. Ligand asserts that Viking materially breached its obligation to use commercially reasonable efforts for the program's development and commercialization. Viking disputes this termination, while Ligand intends to vigorously enforce its rights.
B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND
B. Metzler seel. Sohn & Co. AG has invested $1.30 million in Ligand Pharmaceuticals (NASDAQ:LGND) by purchasing 6,879 shares in Q4, bringing institutional ownership to approximately 91.28%. Despite this, company insiders, including the CFO and a director, have recently sold shares totaling about $6.39 million. Ligand Pharmaceuticals reported strong quarterly earnings, beating estimates with $2.02 EPS and $59.67 million in revenue, and has issued a positive FY2026 EPS guidance of $8.00–$9.00.
Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs
Ligand Pharmaceuticals has entered into a definitive merger agreement to acquire XOMA Royalty for $39.00 per share in cash, along with contingent value rights (CVRs) tied to a CVR Trust. The deal is contingent on XOMA Royalty stockholder approval, HSR clearance, and a holding company reorganization and CVR spin. Ligand has also secured voting and support agreements from holders representing approximately 47% of XOMA Royalty's common shares to facilitate the transaction.
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal
Ligand Pharmaceuticals announced its agreement to acquire XOMA Royalty Corporation for $739 million in cash, equating to $39.00 per share plus a contingent value right tied to Janssen litigation proceeds. This acquisition will significantly expand Ligand's biopharma royalty portfolio by adding seven commercial products and over 100 development-stage assets. Ligand expects the deal to be immediately accretive, raising its 2026 adjusted EPS guidance to $8.50–$9.50 and projecting an additional $1.50 per share to adjusted EPS in 2027.
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals has announced its intent to acquire XOMA Royalty for $39.00 per share, an equity value of approximately $739 million, plus a non-transferable CVR tied to ongoing litigation. This acquisition is set to expand Ligand's royalty portfolio to over 200 assets, adding seven marketed products, and is expected to close in Q3 2026. Ligand has also raised its 2026 financial guidance, anticipating the transaction to be accretive to adjusted EPS by $1.50 in 2027.
Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND
Impax Asset Management Group plc reduced its stake in Ligand Pharmaceuticals Incorporated by 17.5%, selling 35,000 shares and now holding 165,208 shares valued at approximately $31.24 million. Despite this sale, Ligand Pharmaceuticals reported strong quarterly results with EPS of $2.02 and revenue of $59.67 million, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $247.29. Insider selling was also noted, with executives selling shares totaling over $1.6 million, while institutional investors collectively own 91.28% of the company's stock.
Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND
Assetmark Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 4,933.3%, now owning 6,191 shares valued at approximately $1.17 million. Analysts maintain a "Moderate Buy" consensus with a price target of $247.29, following strong quarterly earnings where Ligand reported $2.02 EPS (beating estimates by $0.56) and revenue of $59.67 million, up 39.5% year-over-year. The company also provided a positive FY2026 EPS guidance of $8.00–$9.00.
Ligand (NASDAQ: LGND) posts strong 2025 growth and seeks approval for expanded equity plan
Ligand Pharmaceuticals (LGND) is seeking stockholder approval for an expanded equity plan at its June 5, 2026, annual meeting, following a strong financial performance in 2025. The company reported a 48% increase in royalty revenue and a 42% rise in adjusted EPS, driven by its royalty-focused biopharmaceutical model and successful partner product launches. The proposed changes to the 2002 Stock Incentive Plan include increasing the share reserve by 600,000 shares, removing the fungible pool formula, and updating director compensation limits, aimed at maintaining competitive employee and director incentives.
LGND Financials: Revenue Breakdown, Margins & Competitor Comparison
The article analyzes Ligand Pharmaceuticals Inc (LGND) financials, highlighting its revenue breakdown, profitability margins, and competitive position. Kyprolis is LGND's largest revenue contributor, accounting for 18.5% of total sales. The company demonstrates strong profitability with an 81.42% gross margin and a 75.06% net margin, outperforming competitors like AMRX in efficiency.
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Aberdeen Group plc has reduced its stake in Ligand Pharmaceuticals Incorporated by 37.1% during the fourth quarter, selling over 70,000 shares. Despite this reduction and recent insider selling, Ligand Pharmaceuticals reported strong quarterly results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with a target price of $245.86. Institutional investors collectively own a significant portion of the company's stock at 91.28%.
Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares
John L. LaMattina, a director at Ligand Pharmaceuticals (NASDAQ: LGND), exercised non-qualified stock options for 2,161 shares at $114.15 per share and subsequently sold all those shares for $200.76 per share in an open-market transaction. Following these transactions on March 6, 2026, LaMattina directly holds 30,724 shares of Ligand common stock, with the option position now fully exercised. The net sale amounted to 2,161 shares, valued at $433,842.
